Selvita S.A. (SLV) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenues increased 18% year-over-year to PLN 91.3 million, driven by strong growth in both Drug Discovery and Drug Development segments.

• Adjusted EBITDA rose 28% year-over-year to PLN 14.9 million, reflecting higher commercial revenues.

• Net loss narrowed to PLN -986 thousand (PLN -223 thousand excluding incentive scheme), a significant improvement from Q1 2024.

• Backlog as of May 2025 remained stable at PLN 249.9 million, with Drug Development segment backlog up 7% year-over-year.

Financial highlights

• Total assets at March 31, 2025: PLN 632.6 million; equity: PLN 318.2 million.

• Cash and equivalents decreased to PLN 15.5 million from PLN 22.5 million at year-end 2024.

• Operating cash flow was PLN 10.2 million; total net cash flow was negative at PLN -7.0 million.

• EPS improved to PLN -0.05 from PLN -0.12 year-over-year.

• No dividend declared or paid for the period.

Outlook and guidance

• Financial position remains solid with sufficient liquidity and open credit lines totaling EUR 5 million.

• Key risks for upcoming quarters include client acquisition, US market sentiment, regulatory changes, and currency fluctuations.

• Commercialization of acquired entities and investments in sales, marketing, and laboratory infrastructure are expected to impact future results.